This forum is for discussions relating to Systems Pharmacology Approaches. Here is the definition of Quantitative Systems Pharmacology, as defined by in an NIH White Paper by the QSP Workshop Group – October, 2011
For discussions that are specific to regions, such as ISOP chapters meeting etc. For discussions hosted here in languages other than English.
For discussions that are specific to a given tool or repository. (NONMEM, R, Monolix, WinBUGs, STAN, SAS, MATLAB, , etc)
About the ISOP Pharmacometrics Study Group
For news and announcements of a non-commercial nature.
The Statistics and Pharmacometrics Interest Group (SxP) was named in 2016 and is chartered by both the American Statistical Association (ASA) and International Society of Pharmacometrics (ISOP). This Interest Group promotes collaboration between Statisticians and Pharmacometricians, to enable each discipline to learn and grow from the other and to develop innovative approaches to model informed drug development.
The ISoP student community seeks to foster the interest in pharmacometrics by promoting communication among trainees from various disciplines aiming for efficient drug development and rational drug treatment in patients. The main focus of this community is to create a dynamic platform for educational and scientific events that allows trainees to exchange and broaden their knowledge in this field. Furthermore, peers from all over the world now have the opportunity to interact and support each other’s professional development. The ISoP student community is composed of trainee members from academic institutes across the globe, and whoever interested is encouraged to join by becoming a member. This category is to support discussions in and around the Student Community of ISOP.
Designed for non-tool specific discussions relating to POP PK and PKPD modeling. For example, model evaluation, data standards, covariate selections, etc. For tool-specific discussions use Tools category.
This forum will be used to initiate discussions related to the handling of data and supportive programming for Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) or Pharmacometric analysis. We welcome discussions on programming issues, tips, best practices, and standardization across industry and academics.
This category is for ISoP/ACCP Clinical Pharmacometrics Special Interest Group (SIG) communications. Information for the Clinical Pharmacometrics SIG can be found here. The Leadership Team can also be contacted directly by email, firstname.lastname@example.org.
For discussions relating to how we use quantitative approaches throughout the various stages of Drug Development.
Discussion about this site, its organization, how it works, and how we can improve it.
For community developed online tutorials, topics related to education, curriculum for pharmacometrics, and effective communication of pharmacometric approaches.
To be used for description of pharmacometric sites and resources available to our community of users.
For physiologic based PK (PBPK) related discussions
This category will set ground for rules and etiquette in the discussion forum
This category will be used to have open discussions regarding workflows and infrastructures in pharmacometrics. This will serve as the playground for generation of consensus and ideas for refactoring existing flows and development of new open source tools.